Cells, 2022 The anti-thymic stromal lymphopoietin antibody (tezepelumab) has therapeutical potential for inadequately controlled asthma. However, evidence comparing tezepelumab with other biologics is scarce.
Koichi Ando +2 more
exaly +3 more sources
Tezepelumab: redefining TSLP blockade in severe asthma through mechanistic precision and translational pharmacology [PDF]
Frontiers in PharmacologyApproximately 40%–50% of patients prescribed GINA Step 4–5 ICS/LABA therapy remain inadequately controlled, and existing biologics are restricted by phenotypic eligibility criteria that exclude the substantial type 2-low patient population.
Ghaith K. Mansour +2 more
doaj +2 more sources
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
New England Journal of Medicine, 2021 Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patients with severe, uncontrolled asthma require further assessment.We conducted a phase 3, multicenter, randomized, double-blind, placebo ...
Janet Griffiths +2 more
exaly +4 more sources
Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
Journal of Asthma and Allergy, 2022 Zaid Zoumot,1 Nasser Al Busaidi,2 Wail Tashkandi,3 Ahmed A Aljohaney,4 Said Isse,1 Kota Vidyasagar,5 Kingsley Nnanna Ukwaja6 1Respiratory Institute Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; 2Department of Pulmonology, Royal Hospital ...
Kota Vidyasagar, Wail A Tashkandi
exaly +2 more sources
Tezepelumab in near-fatal asthma requiring VV-ECMO [PDF]
Respiratory Medicine Case ReportsPhase III studies have demonstrated that the anti-TSLP biologic tezepelumab significantly reduces asthma exacerbations in severe asthma, regardless of endotype. However, evidence on its use in near-fatal asthma is lacking. Tezepelumab's ability to reduce
Elisa Bentivegna +8 more
doaj +2 more sources
The emerging role of anti-thymic stromal lymphopoietin monoclonal antibody (Tezepelumab) in comorbid and non-comorbid CRSwNP patients: a scoping review [PDF]
Brazilian Journal of OtorhinolaryngologyObjective: This systematic review aims to evaluate the effectiveness of Tezepelumab, a monoclonal antibody targeting the thymic stromal lymphopoietin, in patients affected by chronic rhinosinusitis with nasal polyposis, both with and without comorbid ...
Antonio Moffa +6 more
doaj +2 more sources
Tezepelumab in severe asthma: chest computed tomography assessment of airway remodeling and clinical remission [PDF]
Frontiers in PharmacologyIntroductionSevere asthma is characterized by persistent uncontrolled symptoms despite optimal standard therapy and/or by the need for high-intensity treatment to maintain control.
Chiara Lupia +15 more
doaj +2 more sources
Mucus Plugging as a Treatable Trait Across the Asthma–COPD Spectrum: The Role of Type 2 Cytokine Blockade and Quantitative Imaging [PDF]
BiomedicinesBackground: Airway mucus plugging is a key but long-overlooked mechanism of persistent airflow obstruction in both asthma and chronic obstructive pulmonary disease (COPD).
Pier-Valerio Mari +9 more
doaj +2 more sources
One size does not fit all: uncontrolled T2 inflammation on tezepelumab—a case series [PDF]
Allergy, Asthma & Clinical ImmunologyBackground Tezepelumab is the most recent human monoclonal antibody in the therapeutic arsenal of patients with severe uncontrolled asthma. It neutralizes thymic stromal lymphopoietin (TSLP).
Arianne Tardif +3 more
doaj +2 more sources
Sequential Use of Tezepelumab and Bronchoscopic Lung Volume Reduction With Endobronchial Valves in a Patient With Severe Asthma‐COPD Overlap and Heterogeneous Emphysema: A Case Report [PDF]
Respirology Case ReportsAsthma‐COPD overlap (ACO) carries greater symptom burden, frequent exacerbations and impaired quality of life compared with asthma or COPD alone. Evidence‐based advanced therapies are lacking, and management is typically extrapolated from existing ...
Jonas Herth, Daniel Franzen
doaj +2 more sources